In a bid to bolster its oncology portfolio, AbbVie has agreed to partner with Genmab to jointly develop and commercialise three of its clinical-stage antibody programmes: epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. As part of the deal, which is worth up to US$3.9 B, the companies will also develop up to four additional candidates using Genmab’s DuoBody technology across solid tumours and haematological malignancies. The deal comes as AbbVie is under pressure to find new growth drivers as it faces multiple patent expirations in the near-term including Humira which faces the threat of US biosimilars in 2023.